We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Siemens Healthineers - Laboratory Diagnostics

Provides advanced laboratory diagnostics solutions for the medical industry read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Lack of Autoantibodies Against Related Proteins in Collagenous Colitis

By LabMedica International staff writers
Posted on 21 Jun 2022
Print article
Image: Histological features of collagenous colitis (Photo courtesy of Michael Bonert, MD, FRCPC)
Image: Histological features of collagenous colitis (Photo courtesy of Michael Bonert, MD, FRCPC)

Collagenous colitis (CC) is an inflammatory disorder in the colonic mucosa that predominantly affects elderly women and causes chronic, non-bloody diarrhea with normal or close to normal endoscopic findings.

The histological criteria for CC are a thickened sub-epithelial collagen layer (> 10 µm) in the extracellular matrix (ECM) of the mucosa, epithelial damage and presence of an inflammatory infiltrate in the lamina propria. CC shares many of the characteristics found in autoimmune diseases, but no autoantibodies have been identified. In CC, an imbalance in collagen turnover is evident.

Gastroenterologists at the Skåne University Hospital (Malmö, Sweden) included in a study, 66 women with CC. The mean age at inclusion was 60 years (range 31–74 years) and mean age at diagnosis was 55 years (range 28–69 years). The size of the control groups differed, but they were selected from the same cohort consisting of 100 healthy female blood donors. The mean age of the total control group was 41.7 years (range 19–69).

In-house enzyme-linked immunosorbent assays (ELISAs) were set up for analysis of anti-IgM and IgG antibodies against collagen type III (Col III and IV). Analyses of antibodies against matrix metalloproteinase-9 (MMP-9 and Tenascin-C (TNC) were conducted by in-house ELISAs and another in-house ELISA was set up for analysis of IgM and IgG antibodies against tissue inhibitors of metalloproteinase (TIMP-1). Anti-Saccharomyces cerevisiae antibodies (ASCA) IgG were analyzed by a fluorescent enzyme immunoassay method (FEIA) for which the reference value is set > 10 U/mL (Orgentec Diagnostika, Mainz, Germany). Thyroid peroxidase (TPO) antibodies were analyzed by a chemiluminescence enzyme immunological method (Siemens Healthcare GmbH, Erlangen, Germany).

The investigators reported that there was no difference in prevalence of these collage-associated autoantibodies between CC patients and controls. Sixteen patients expressed one type of autoantibody, whereas two patients expressed two different types. The mean disease duration was significantly lower in the subjects who expressed collagen-associated autoantibodies (3.7 years; range 1–14), compared to those who did not (6.4 years; range 1–22). The presence of autoantibodies against TPO and ASCA was slightly increased compared to controls, but not statistically significant. Increased levels of total IgE were equally present in the CC patients and the control group, and there was no correlation between total IgE-positivity and presence of any autoantibodies.

The authors concluded that no increased presence of the investigated antibodies could be found in the present study of CC. Neither could antibodies against ASCA or TPO, or elevated levels of IgE, be found. Consequently, no association was found between CC and these proteins, even though this may not be generalizable to other compounds in the collagen layer. The study was published on June 6, 2022 in the journal BMC Immunology.

Related Links:
Skåne University Hospital 
Orgentec Diagnostika 
Siemens Healthcare GmbH 

Gold Supplier
SARS-CoV-2 Antigen Rapid Test
RapiSafe SARS-CoV-2 Antigen Rapid Test (Professional use)
Cytomegalovirus ELISA Test
Captia Cytomegalovirus (CMV) IgM EIA
POC Pathogen Detection & Gene Expression System
Sal6830 Mobile Workstation
Automatic Fecal Analyzer

Print article
IIR Middle East



view channel
Image: OneDraw Blood Collection Device significantly reduces obstacles for drawing blood (Photo courtesy of Drawbridge Health)

Near Pain-Free Blood Collection Technology Enables High-Quality Testing

Blood tests help doctors diagnose diseases and conditions such as cancer, diabetes, anemia, and coronary heart disease, as well as evaluate organ functionality. They can also be used to identify disease... Read more


view channel
Image: The global infectious disease IVD market is expected to hit USD 57 billion by 2030 (Photo courtesy of Pexels)

Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030,... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.